Unichem Laboratories (UNICHEMLAB) Fundamentals 2026 — P/E 14.7x, Revenue Analysis | SniperIQ
Unichem Laboratories (UNICHEMLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹3,721 Crore, trading at ₹528.55 on the NSE. This SniperIQ fundamentals page covers Unichem Laboratories's valuation (P/E 14.7x, P/B 1.4x), profitability (net margin 11.5%), revenue (₹2,202 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Unichem Laboratories's market cap?
Unichem Laboratories (UNICHEMLAB) has a market capitalization of approximately ₹3,721 Crore, trading at ₹528.55 on the NSE. Market cap moves with the live share price.
What is Unichem Laboratories's P/E ratio?
Unichem Laboratories's trailing twelve-month P/E ratio is 14.7x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Unichem Laboratories?
Unichem Laboratories runs a net profit margin of 11.5%, a gross margin of 36.1%, and an operating margin of 2.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Unichem Laboratories generate?
Unichem Laboratories reported revenue of ₹2,202 Crore for fiscal year 2026, with net income of ₹253 Crore and earnings per share (EPS) of 35.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Unichem Laboratories pay a dividend?
Unichem Laboratories does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Unichem Laboratories financially healthy?
Unichem Laboratories carries a debt-to-equity ratio of 0.18x and a current ratio of 2.48x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Unichem Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Unichem Laboratories (UNICHEMLAB) the key facts are: market cap ₹3,721 Crore, P/E 14.7x, revenue ₹2,202 Crore, 52-week range 278.2-687.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Unichem Laboratories's full fundamentals live
Get Unichem Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.